siRNA Mediated Modulation of Lynx1 for Cognitive Enhancement

Information

  • Research Project
  • 8272528
  • ApplicationId
    8272528
  • Core Project Number
    R43MH094004
  • Full Project Number
    5R43MH094004-02
  • Serial Number
    094004
  • FOA Number
    PA-08-142
  • Sub Project Id
  • Project Start Date
    6/3/2011 - 14 years ago
  • Project End Date
    4/30/2014 - 11 years ago
  • Program Officer Name
    GRABB, MARGARET C.
  • Budget Start Date
    5/1/2012 - 13 years ago
  • Budget End Date
    4/30/2014 - 11 years ago
  • Fiscal Year
    2012
  • Support Year
    02
  • Suffix
  • Award Notice Date
    5/26/2012 - 13 years ago
Organizations

siRNA Mediated Modulation of Lynx1 for Cognitive Enhancement

DESCRIPTION (provided by applicant): The proposed project details a biologic strategy for the therapeutic targeting of nicotinic receptors of the cholinergic system for the treatment of mental and neurological disorders. The cholinergic system is an important modulatory neurotransmitter system, regulating reward, learning and memory, attention, and cognitive functions. The nicotinic acetylcholine receptor, a major receptor of the cholinergic system, is regulated by modulatory accessory proteins which bind to nicotinic acetylcholine receptors and dampen their function. Biological proof of concept studies in our mouse models indicate that regulating cholinergic tone has a beneficial enhancement of complex circuits in the brain, leading to enhanced learning and memory function. In order to develop a therapeutic intervention recapitulating this cognitive enhancement, we propose to develop a biological therapeutic to enhance cholinergic tone in the brain through accessory molecules to nicotinic receptors. Because the blood brain barrier is the most challenging problem facing the delivery of the macromolecules to neurons in the brain, we propose several strategies for optimizing delivery based on peptides with demonstrated ability to deliver therapeutic candidates past the blood- brain barrier. We will couple the most efficient translocators. We will test the functional inhibition by therapeutic candidates on our established nicotinic receptor cell lines and assays. In addition, we will label potential carrier molecules to assess their blood-brain penetrability, and finally test the efficacy of candidates in vivo in our mouse models. If successful the outcome will lead to the development of a therapeutic candidate to treat cognitive and memory impairments associated with mental and neurological disorders, such as schizophrenia, Alzheimer's and Parkinson's disease, and depression.

IC Name
NATIONAL INSTITUTE OF MENTAL HEALTH
  • Activity
    R43
  • Administering IC
    MH
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    328348
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    242
  • Ed Inst. Type
  • Funding ICs
    NIMH:328348\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    OPHIDION, INC.
  • Organization Department
  • Organization DUNS
    825379659
  • Organization City
    PASADENA
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    911073658
  • Organization District
    UNITED STATES